Dr. Nigel Whittle has over 25 years’ international experience in the life science industry, in a wide range of senior scientific, commercial and managerial roles. He obtained an honors degree in Biochemistry from the University of Oxford, then went on to complete his Ph.D. in ground-breaking research at the Cancer Research UK Laboratories (London, UK). He has since worked for a number of premier biotechnology companies, including Genentech, Celltech and Cantab Pharmaceuticals. As VP of Project Management with Cantab he was responsible for company product development, taking proprietary products into late stage Clinical Trials.

Dr. Whittle was recruited by the IPGroup private equity firm to drive the programme of technology commercialization from Kings College London, including starting up Proximagen Neurosciences, which he helped float on AIM, raising £13 million. On leaving the company, Dr. Whittle joined UK Trade & Investment, working on two programmes to identify and broker high-value business deals, working with a portfolio of established overseas pharmaceutical companies to secure investment into the UK’s R&D capabilities worth over £100 million pounds. He also worked with Sagentia Ltd in 2016 to work in the medical group, assisting client companies in solving complex problems in science and technology.

Request Proposal Form

Elevate Healthcare Together: Your Pharma Proposal Paves the Path for Innovative Solutions. Join Hands with Us in Advancing Medical Excellence and Improving Lives.